Sustained Cognitive Benefits wiht Lecanemab

New data presented at the American Academy of Neurology (AAN) annual meeting in San Diego reveals that extended treatment with lecanemab, an anti-amyloid antibody, yields lasting positive effects for patients experiencing the initial phases of Alzheimer’s. The findings stem from an open-label extension of the CLARITY AD study, suggesting that the drug can modify the course of the disease over an extended period.

The research indicates that continuous lecanemab therapy leads to important changes in plasma beta-amyloid 42/40 levels, which correlates with improved cognitive performance as measured by various cognitive assessments. This suggests a potential for long-term stabilization of cognitive function.

Comparative Analysis: Lecanemab vs. Natural Disease Progression

A comparison between patients treated with lecanemab and a control group from the Alzheimer’s Disease Neuroimaging Initiative (ADNI) revealed notable differences in the rate of cognitive decline. While both groups initially showed similar progression during the placebo-controlled phase of the CLARITY AD study, the open-label extension demonstrated that lecanemab reduced the progression to the next disease stage by 30%, as indicated by CDR-SB scores.

Impact on Patients with low tau levels

Notably, patients with reduced or absent Tau levels (below 1.06 SUVRs, as measured by PET scans) experienced the most significant benefits from lecanemab therapy. These individuals showed either maintained or improved cognitive performance, highlighting the potential for early intervention.

Consistent trends were also observed in ADAS-Cog 14 test scores and ADCS MCI-ADL assessments, further supporting the positive impact of lecanemab on cognitive function.

Safety Profile and Adverse Effects

While the cognitive benefits are promising,the safety profile of lecanemab remains a key consideration. The study reported serious adverse events in 20.5% of the 1,616 participants involved in the main study and its extension.

Specific side effects included Amyloid-Related Imaging Abnormalities with Edema (ARIA-E) in 14.7% of participants and Amyloid-Related Imaging Abnormalities with Hemorrhage (ARIA-H) in 23.8%. Intracerebral hemorrhages were observed in 0.7% of cases,with three fatalities potentially linked to the treatment.

Expert Perspectives and Clinical Implications

According to Christopher Van Dyck of Yale University, these findings represent the first evidence of sustained benefits from anti-amyloid therapy over time. He emphasized the importance of initiating treatment early and continuing it long-term for optimal outcomes.

The subjects with lower levels of Tau and amyloid show a particularly robust stabilization of symptoms.
Christopher Van Dyck, Yale University

Van dyck also noted that the drug’s effectiveness appears more pronounced in patients with less advanced disease.

Regulatory Landscape and Recommendations

Lecanemab,which selectively targets soluble beta-amyloid protofibrils,has received FDA approval for treating early-stage Alzheimer’s based on data from the CLARITY AD study. However, the drug carries a warning regarding the potential for ARIA advancement, and the American academy of neurology (AAN) has issued recommendations to minimize this risk.

In Europe, the EMA has approved the drug for patients with one or no copies of the ApoE4 gene, a subgroup at higher risk of developing ARIA.

Previous Findings and Long-Term outcomes

The initial CLARITY AD study demonstrated that lecanemab reduced cognitive decline compared to placebo,albeit with associated adverse events. the primary efficacy parameter, the CDR-SB score, showed an average increase of 1.21 points after 18 months in treated patients, compared to 1.66 points in the placebo group, representing a difference of 0.45 points. All secondary objectives of the study were also met.

The open-label extension also assessed subjects who started therapy later, transitioning from placebo to lecanemab.These individuals showed biomarker improvements within three months, which were sustained with continuous therapy.

Importantly,no new safety signals emerged with prolonged management,and the ARIA rate stabilized after six months,reaching levels similar to those in the placebo group.

The Future of Alzheimer’s treatment

These data strengthen the idea that Lecanemab is really a modifying therapy.
Dennis Selkoe, Brigham and Women’s Hospital

Research suggests that treatment should begin early and, if well-tolerated, continue for at least three years. Though, the optimal duration of therapy remains unclear and should be determined on a case-by-case basis by physicians and patients, according to Van Dyck.

As of 2025,Alzheimer’s disease affects millions worldwide,with numbers projected to increase significantly in the coming decades. The development of disease-modifying therapies like lecanemab represents a crucial step forward in addressing this global health challenge. Continued research and monitoring of long-term outcomes are essential to optimize treatment strategies and improve the lives of individuals affected by Alzheimer’s.